ChromaDex (NASDAQ:CDXC) Given New $8.00 Price Target at Roth Mkm

ChromaDex (NASDAQ:CDXC) had its target price upped by equities researchers at Roth Mkm from $6.00 to $8.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Roth Mkm’s target price suggests a potential upside of 16.28% from the stock’s current price.

Separately, HC Wainwright lifted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday.

ChromaDex Stock Up 12.6 %

Shares of NASDAQ:CDXC traded up $0.77 during trading on Wednesday, hitting $6.88. 1,033,558 shares of the stock traded hands, compared to its average volume of 502,459. The company has a market cap of $522.42 million, a price-to-earnings ratio of 688.00 and a beta of 1.88. The company has a fifty day moving average price of $3.63 and a two-hundred day moving average price of $3.26. ChromaDex has a 52-week low of $1.32 and a 52-week high of $6.91.

ChromaDex (NASDAQ:CDXC) last posted its earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. The firm had revenue of $25.58 million during the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same period in the previous year, the firm earned ($0.01) EPS. On average, equities research analysts predict that ChromaDex will post 0.01 EPS for the current fiscal year.

Insider Activity

In other news, Director Kristin Patrick sold 23,000 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $3.57, for a total transaction of $82,110.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 9.64% of the company’s stock.

Institutional Trading of ChromaDex

Several institutional investors and hedge funds have recently bought and sold shares of CDXC. SG Americas Securities LLC purchased a new stake in ChromaDex during the first quarter worth about $54,000. Acadian Asset Management LLC purchased a new stake in ChromaDex during the first quarter worth about $67,000. Lazard Asset Management LLC purchased a new stake in ChromaDex during the first quarter worth about $43,000. Perritt Capital Management Inc. purchased a new stake in shares of ChromaDex during the first quarter worth approximately $139,000. Finally, Miracle Mile Advisors LLC purchased a new stake in shares of ChromaDex during the second quarter worth approximately $27,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.